Update on methotrexate as the anchor drug for rheumatoid arthritis.

No abstract is available for this paper.

• Publication year

  2013

• Venue

  Bulletin of the Hospital for Joint Diseases

• Publication date

  Unknown publication date

• Fields of study

  Medicine

• Identifiers
  PMID 24219036
• External record

  Open on Semantic Scholar

• Source metadata

  Semantic Scholar, PubMed

• No claims are published for this paper.

• No concepts are published for this paper.

• RAPID3, an index of only 3 patient self-report core data set measures, but not ESR, recognizes incomplete responses to methotrexate in usual care of patients with rheumatoid arthritis.

  2013cited by this paper
• Evidence that the strategy is more important than the agent to treat rheumatoid arthritis. Data from clinical trials of combinations of non-biologic DMARDs, with protocol-driven intensification of therapy for tight control or treat-to-target.

  2013cited by this paper
• A randomized comparative effectiveness study of oral triple therapy versus etanercept plus methotrexate in early aggressive rheumatoid arthritis: the treatment of Early Aggressive Rheumatoid Arthritis Trial.

  2012cited by this paper
• Methotrexate--the anchor drug--an introduction.

  2010cited by this paper
• Treating rheumatoid arthritis to target: recommendations of an international task force

  2010cited by this paper
• Underestimation of the efficacy, effectiveness, tolerability, and safety of weekly low-dose methotrexate in information presented to physicians and patients.

  2010cited by this paper
• Risk and management of liver toxicity during methotrexate treatment in rheumatoid and psoriatic arthritis: a systematic review of the literature.

  2009cited by this paper
• Single, intra-articular treatment with 6 ml hylan G-F 20 in patients with symptomatic primary osteoarthritis of the knee: a randomised, multicentre, double-blind, placebo controlled trial

  2009cited by this paper
• Radiographic measures to assess patients with rheumatoid arthritis: advantages and limitations.

  2009cited by this paper
• Systematic Review : Comparative Effectiveness and Harms of Disease-Modifying Medications for Rheumatoid Arthritis

  2008cited by this paper
• Multinational evidence-based recommendations for the use of methotrexate in rheumatic disorders with a focus on rheumatoid arthritis: integrating systematic literature research and expert opinion of a broad international panel of rheumatologists in the 3E Initiative

  2008cited by this paper
• Tumor necrosis factor alpha inhibitors, methotrexate or both? An inquiry into the formal evidence for when they are to be used in rheumatoid arthritis.

  2008cited by this paper
• Systematic Review: Comparative Effectiveness and Harms of Disease-Modifying Medications for Rheumatoid Arthritis

  2008cited by this paper
• American College of Rheumatology 2008 recommendations for the use of nonbiologic and biologic disease-modifying antirheumatic drugs in rheumatoid arthritis.

  2008cited by this paper
• Are excellent systematic reviews of clinical trials useful for patient care?

  2008cited by this paper
• Mortality in rheumatoid arthritis: 2008 update.

  2008cited by this paper
• RAPID3 (Routine Assessment of Patient Index Data 3), a Rheumatoid Arthritis Index Without Formal Joint Counts for Routine Care: Proposed Severity Categories Compared to Disease Activity Score and Clinical Disease Activity Index Categories

  2008cited by this paper
• Rheumatoid arthritis, alcohol, leflunomide and methotrexate. Can changes to the BSR guidelines for leflunomide and methotrexate on alcohol consumption be justified?

  2008cited by this paper
• Limitations of the randomized controlled trial in evaluating population-based health interventions.

  2007cited by this paper
• QUEST-RA: quantitative clinical assessment of patients with rheumatoid arthritis seen in standard rheumatology care in 15 countries

  2007cited by this paper
• Intensive treatment with methotrexate in early rheumatoid arthritis: aiming for remission. Computer Assisted Management in Early Rheumatoid Arthritis (CAMERA, an open-label strategy trial)

  2007cited by this paper
• Clinical trials versus registries in coronary revascularization: which are more relevant?

  2007cited by this paper
• Aggressive combination therapy with intra-articular glucocorticoid injections and conventional disease-modifying anti-rheumatic drugs in early rheumatoid arthritis: second-year clinical and radiographic results from the CIMESTRA study

  2007cited by this paper
• Genetics of Alcoholic Liver Disease and Nonalcoholic Fatty Liver Disease

  2007cited by this paper
• The PREMIER study: A multicenter, randomized, double-blind clinical trial of combination therapy with adalimumab plus methotrexate versus methotrexate alone or adalimumab alone in patients with early, aggressive rheumatoid arthritis who had not had previous methotrexate treatment.

  2006cited by this paper
• The limitations of 'evidence-based' public health.

  2006cited by this paper
• Evidence-based practice and practice-based evidence

  2006cited by this paper
• Stable occurrence of knee and hip total joint replacement in Central Finland between 1986 and 2003: an indication of improved long-term outcomes of rheumatoid arthritis

  2006cited by this paper
• Methotrexate and Hepatic Toxicity in Rheumatoid Arthritis and Psoriatic Arthritis

  2006cited by this paper
• Grading strength of recommendations and quality of evidence in clinical guidelines: report from an american college of chest physicians task force.

  2006cited by this paper
• Further development of a physical function scale on a MDHAQ [corrected] for standard care of patients with rheumatic diseases.

  2005cited by this paper
• Further Development of a Physical Function Scale on a Multidimensional Health Assessment Questionnaire for Standard Care of Patients with Rheumatic Diseases ASSESSMENT VALIDITY RELIABILITY RHEUMATOID ARTHRITIS ACTIVITIES OF DAILY LIVING

  2005cited by this paper
• Patients seen for standard rheumatoid arthritis care have significantly better articular, radiographic, laboratory, and functional status in 2000 than in 1985.

  2005cited by this paper
• Clinical and radiographic outcomes of four different treatment strategies in patients with early rheumatoid arthritis (the BeSt study): a randomized, controlled trial.

  2005cited by this paper
• Has rheumatoid arthritis become a milder disease

  2005cited by this paper
• Presentation and analysis of data on radiographic outcome in clinical trials: experience from the TEMPO study.

  2005cited by this paper
• Combination of infliximab and methotrexate therapy for early rheumatoid arthritis: a randomized, controlled trial.

  2004cited by this paper
• Radiographic progression depicted by probability plots: presenting data with optimal use of individual values.

  2004cited by this paper
• Evidence from clinical trials: Can we do better?

  2004cited by this paper
• Effect of a treatment strategy of tight control for rheumatoid arthritis (the TICORA study): a single-blind randomised controlled trial.

  2004cited by this paper
• Clinical trials in rheumatic diseases: designs and limitations.

  2004cited by this paper
• Relative versus absolute goals of therapies for RA: ACR 20 or ACR 50 responses versus target values for "near remission" of DAS or single measures.

  2004cited by this paper
• Long term safety of methotrexate in routine clinical care: discontinuation is unusual and rarely the result of laboratory abnormalities

  2004cited by this paper
• When are observational studies as credible as randomised trials?

  2004cited by this paper
• Radiographic progression is getting milder in patients with early rheumatoid arthritis. Results of 3 cohorts over 5 years.

  2004cited by this paper
• Methotrexate as the "anchor drug" for the treatment of early rheumatoid arthritis.

  2003cited by this paper
• Reduction in long-term functional disability in rheumatoid arthritis from 1977 to 1998:a longitudinal study of 3035 patients.

  2003cited by this paper
• Add-on or step-up trials for new drug development in rheumatoid arthritis: a new standard?

  2003cited by this paper
• Adalimumab, a fully human anti-tumor necrosis factor alpha monoclonal antibody, for the treatment of rheumatoid arthritis in patients taking concomitant methotrexate: the ARMADA trial.

  2003cited by this paper
• Etanercept versus methotrexate in patients with early rheumatoid arthritis: two-year radiographic and clinical outcomes.

  2002cited by this paper
• Methotrexate and mortality in patients with rheumatoid arthritis: a prospective study.

  2002cited by this paper
• Evidence from clinical trials and long-term observational studies that disease-modifying anti-rheumatic drugs slow radiographic progression in rheumatoid arthritis: updating a 1983 review.

  2002cited by this paper
• Determination of the minimal clinically important difference in rheumatoid arthritis joint damage of the Sharp/van der Heijde and Larsen/Scott scoring methods by clinical experts and comparison with the smallest detectable difference.

  2002cited by this paper
• The double-blind, randomized, placebo-controlled trial: gold standard or golden calf?

  2001cited by this paper
• Response to methotrexate treatment is associated with reduced mortality in patients with severe rheumatoid arthritis.

  2000cited by this paper
• A comparison of etanercept and methotrexate in patients with early rheumatoid arthritis.

  2000cited by this paper
• Infliximab (chimeric anti-tumour necrosis factor α monoclonal antibody) versus placebo in rheumatoid arthritis patients receiving concomitant methotrexate: a randomised phase III trial

  1999cited by this paper
• Lower disease activity and disability in Swedish patients with rheumatoid arthritis in 1995 compared with 1978.

  1999cited by this paper
• Targeted therapies in rheumatoid arthritis: the need for action.

  1999cited by this paper
• Infliximab (chimeric anti-tumour necrosis factor alpha monoclonal antibody) versus placebo in rheumatoid arthritis patients receiving concomitant methotrexate: a randomised phase III trial. ATTRACT Study Group.

  1999cited by this paper
• Conventional monotherapy compared to a "sawtooth" treatment strategy in the radiographic progression of rheumatoid arthritis over the first eight years.

  1999cited by this paper
• Problems in the "evidence" of "evidence-based medicine".

  1997cited by this paper
• Why randomized controlled clinical trials do not depict accurately long-term outcomes in rheumatoid arthritis: some explanations and suggestions for future studies.

  1997cited by this paper
• Measures of activity and damage in rheumatoid arthritis: depiction of changes and prediction of mortality over five years.

  1997cited by this paper
• Randomised comparison of combined step-down prednisolone, methotrexate and sulphasalazine with sulphasalazine alone in early rheumatoid arthritis.

  1997cited by this paper
• Rheumatoid Arthritis: Treat Now, Not Later!

  1996cited by this paper
• What is the best source of useful data on the treatment of rheumatoid arthritis: clinical trials, clinical observations, or clinical protocols?

  1995cited by this paper
• Early rheumatoid arthritis: time to aim for remission?

  1995cited by this paper
• Can overall results of clinical trials be applied to all patients

  1995cited by this paper
• Can overall results of clinical trials be applied to all patients?

  1995cited by this paper
• Mortality in rheumatoid arthritis.

  1995cited by this paper
• Rheumatoid arthritis: a medical emergency?

  1994cited by this paper
• Limitations of randomized clinical trials to recognize possible advantages of combination therapies in rheumatic diseases.

  1993cited by this paper
• Radiographic damage in rheumatoid arthritis: description by nonlinear models.

  1992cited by this paper
• Comparison of azathioprine, methotrexate, and the combination of both in the treatment of rheumatoid arthritis. A controlled clinical trial.

  1992cited by this paper
• Trends in the incidence and severity of rheumatoid arthritis.

  1992cited by this paper
• Longterm drug therapy for rheumatoid arthritis in seven rheumatology private practices: II. Second line drugs and prednisone.

  1992cited by this paper
• The case for early intervention in rheumatoid arthritis.

  1992cited by this paper
• Comparison of auranofin, methotrexate, and the combination of both in the treatment of rheumatoid arthritis. A controlled clinical trial.

  1992cited by this paper
• Reevaluating the therapeutic approach to rheumatoid arthritis: the "sawtooth" strategy.

  1990cited by this paper
• The comparative efficacy and toxicity of second-line drugs in rheumatoid arthritis. Results of two metaanalyses.

  1990cited by this paper
• Remodeling the pyramid or remodeling the paradigms concerning rheumatoid arthritis--lessons from Hodgkin's disease and coronary artery disease.

  1990cited by this paper
• Remodeling the pyramid--a concept whose time has come.

  1989cited by this paper
• Rheumatoid arthritis: disappointing long-term outcomes despite successful short-term clinical trials.

  1988cited by this paper
• The natural history of rheumatoid arthritis: a fifteen year follow-up study The prognostic significance of features noted in the first year

  1984cited by this paper
• Severe functional declines, work disability, and increased mortality in seventy-five rheumatoid arthritis patients studied over nine years.

  1984cited by this paper
• Progression of radiological changes in rheumatoid arthritis.

  1984cited by this paper
• An additional basic science for clinical medicine: II. The limitations of randomized trials.

  1983cited by this paper
• Is rheumatoid arthritis becoming less severe?

  1983cited by this paper
• The Long-Term Effects of Treating Rheumatoid Arthritis

  1983cited by this paper
• Work disability in rheumatoid arthritis: effects of disease, social, and work factors.

  1980cited by this paper
• The importance of beta, the type II error and sample size in the design and interpretation of the randomized control trial. Survey of 71 "negative" trials.

  1978cited by this paper

• Targeting synovial fibroblast KCa1.1 channels in rheumatoid arthritis.

  2026cites this paper
• Gastrointestinal adverse events among methotrexate users in rheumatoid arthritis patients: a systematic review and meta-analysis.

  2026cites this paper
• Methotrexate-Associated Hypersensitivity Pneumonitis After 15 Years of Use: A Case Report and Literature Review

  2025cites this paper
• Anticancer activity of Avicennia marina leaves on breast, ovarian and cervical cancer cell lines: In vitro and In silico analyses

  2025cites this paper
• Upadacitinib monotherapy versus methotrexate monotherapy in patients with rheumatoid arthritis: efficacy and safety through 5 years in the SELECT-EARLY randomized controlled trial

  2024cites this paper
• Biomarker combination predicting imminent relapse after discontinuation of biological drugs in patients with rheumatoid arthritis in remission

  2024cites this paper
• Management strategies in rheumatoid arthritis

  2024cites this paper
• Methotrexate - Safe Backbone for the Treatment of Rheumatoid Arthritis.

  2024cites this paper
• Methotrexate intolerance in Rheumatoid Arthritis

  2023cites this paper
• Methotrexate and cardiovascular prevention: an appraisal of the current evidence

  2023influential citation
• Treatment in Patients with Psoriatic Disease and Rheumatoid Arthritis: Seven Case Reports

  2023cites this paper
• Therapeutic Maintenance Level of Methotrexate in Rheumatoid Arthritis: A RBSMR Study

  2022cites this paper
• Examining the safety of relaxed drug monitoring for methotrexate in response to the COVID-19 pandemic

  2022cites this paper
• 2018 Chinese Guidelines for the Diagnosis and Treatment of Rheumatoid Arthritis

  2021cites this paper
• Peripheral Blood Gene Expression Signatures Identify Methotrexate Responders in Patients with Rheumatoid Arthritis

  2020influential citation
• Factors associated with anxiety and depression in rheumatoid arthritis patients: a cross-sectional study

  2020cites this paper
• JTE-952 Suppresses Bone Destruction in Collagen-Induced Arthritis in Mice by Inhibiting Colony Stimulating Factor 1 Receptor.

  2020cites this paper
• Does methotrexate cause interstitial lung disease in rheumatoid arthritis: What is the evidence?

  2020cites this paper
• The Outcome of Stem Cell-Based Therapies on the Immune Responses in Rheumatoid Arthritis.

  2020cites this paper
• Iontophoresis, magnetophoresis, and electroporation

  2020cites this paper
• Risk Factors Associated with Methotrexate Intolerance in Rheumatoid Arthritis Patients

  2020cites this paper
• Study on the relationship between low-dose methotrexate and the concentration and efficacy of polyglutamated methotrexate in the treatment of rheumatoid arthritis

  2020influential citation
• 8 — 1 22 CAN VISUAL OUTCOME AND TREATMENT IN SCLERITIS BE IMPROVED ?

  2019cites this paper
• Safety and effectiveness of iguratimod in patients with rheumatoid arthritis: Final report of a 52-week, multicenter postmarketing surveillance study

  2019cites this paper
• Prevalence of methotrexate intolerance among patients with rheumatoid arthritis using the Arabic version of the methotrexate intolerance severity score

  2019cites this paper
• Monotherapy is a relevant option in rheumatoid arthritis treatment: a literature review.

  2019cites this paper
• Diagnostic and therapeutic challenges in inflammatory eye diseases

  2019cites this paper
• Systematic review and meta-analysis of the efficacy and safety of leflunomide and methotrexate in the treatment of rheumatoid arthritis

  2019cites this paper
• Repurposing existing drugs for cardiovascular risk management: a focus on methotrexate

  2018cites this paper
• Clearing up potential misconceptions about the treatment of rheumatoid arthritis and the use of methotrexate in combination therapy

  2018cites this paper
• Drug Monitoring in Breast Milk: Novel Insights on Pharmacokinetics and Infant Exposure Estimates

  2018cites this paper
• Overview of Rheumatoid Arthritis therapy: Management options in Indonesia

  2018cites this paper
• Systematic review and meta-analysis of the efficacy and safety of Biqi capsule in rheumatoid arthritis patients

  2018cites this paper
• Drugs Used in Rheumatic Disease

  2018cites this paper
• Are gene polymorphisms related to treatment outcomes of methotrexate in patients with rheumatoid arthritis? A systematic review and meta-analysis.

  2017cites this paper
• RÔLE DE POLYMORPHISMES NUCLÉOTIDIQUES DANS LES GÈNESDE L’INTERLEUKINE-4 ET SON RÉCEPTEUR ET DU CORÉCEPTEURCD40, ET DES ALLÈLES HLA-DR, DANS LA PROGRESSION DE LAPOLYARTHRITE INFLAMMATOIRE D’INSTALLATION RÉCENTE

  2017cites this paper
• Systematic review and meta-analysis of the efficacy and safety of leflunomide and methotrexate in the treatment of rheumatoid arthritis.

  2017cites this paper
• Oral to subcutaneous methotrexate dose-conversion strategy in the treatment of rheumatoid arthritis

  2017influential citation
• Methotrexate intolerance in the treatment of rheumatoid arthritis (RA): effect of adding caffeine to the management regimen

  2017cites this paper
• A Novel Approach for Integrating Best Evidence and Patient Preferences into Treatment Recommendations for Rheumatoid Arthritis

  2016cites this paper
• Effects of synthetic and biological disease modifying antirheumatic drugs on lipid and lipoprotein parameters in patients with rheumatoid arthritis.

  2016cites this paper
• Discoveries of conventional synthetic disease modifying anti-rheumatic drugs - Serendipity or flawless reasoning?

  2016cites this paper
• Methotrexate versus leflunomide: Which one to choose?

  2016cites this paper
• Room for more IL-6 blockade? Sarilumab for the treatment of rheumatoid arthritis

  2016cites this paper
• Новые подходы к фармакотерапии ревматоидного артрита: тофацитиниб

  2014cites this paper
• Новые рекомендации по лечению ревматоидного артрита (EULAR, 2013): место метотрексата

  2014cites this paper
• Measuring disease activity in early rheumatoid arthritis: An emerging challenge

  2014cites this paper
• The Past versus the Present, 1980-2004: Reduction of Mean Initial Low-Dose, Long-Term Glucocorticoid Therapy in Rheumatoid Arthritis from 10.3 to 3.6 mg/Day, Concomitant with Early Methotrexate, with Long-Term Effectiveness and Safety of Less than 5 mg/Day

  2014cites this paper
• Evidence that the strategy is more important than the agent to treat rheumatoid arthritis. Data from clinical trials of combinations of non-biologic DMARDs, with protocol-driven intensification of therapy for tight control or treat-to-target.

  2013cites this paper
• Open Access Rheumatology: Research and Reviews Dovepress

  year unknowncites this paper
• Biologics: Targets and Therapy Dovepress Video Abstract Biologic Monotherapy in the Treatment of Rheumatoid Arthritis

  year unknowncites this paper